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Eny2, the mammalian ortholog of yeast Sus1 and drosophila E(y)2, is a nuclear factor that participates in several steps of gene
transcription and in mRNA export. We had previously found that Eny2 expression changes in mouse pancreatic islets during the
metabolic adaptation to pregnancy. We therefore hypothesized that the protein contributes to the regulation of islet endocrine cell
function and tested this hypothesis in rat INS-1E insulinoma cells. Overexpression of Eny2 had no eﬀect but siRNA-mediated
knockdown of Eny2 resulted in markedly increased glucose and exendin-4-induced insulin secretion from otherwise poorly
glucose-responsive INS-1E cells. Insulin content, cellular viability, and the expression levels of several key components of glucose
sensing remained unchanged; however glucose-dependent cellular metabolism was higher after Eny2 knockdown. Suppression of
Eny2 enhanced the intracellular incretin signal downstream of cAMP. The use of speciﬁc cAMP analogues and pathway inhibitors
primarily implicated the PKA and to a lesser extent the EPAC pathway. In summary, we identiﬁed a potential link between the
nuclear protein Eny2 and insulin secretion. Suppression of Eny2 resulted in increased glucose and incretin-induced insulin release
from a poorly glucose-responsive INS-1E subline. Whether these ﬁndings extend to other experimental conditions or to in vivo
physiology needs to be determined in further studies.
1.Introduction
Diabetes mellitus Type 2 (T2D) is usually caused by periph-
eralinsulinresistancetogetherwithinadequateinsulinsecre-
tion by the pancreatic beta cells [1]. The latter represents the
combination of a primary, probably genetically determined,
failure to adapt to increased insulin requirements and sec-
ondary beta cell defects caused by, for example, glucotoxicity
and amyloid depositions [2, 3]. Impaired insulin secretory
function plays a major role both in diabetes manifestation
and progression [4]. Two groups of antidiabetic drugs that
directly target beta cell function are currently in clinical
use. The sulfonylureas act via glucose-independent closure
of KATP channels, and the glucagon-like peptide 1 (GLP-1)
analogues and enhancers augment insulin secretion via the
GLP-1receptorandcAMP.Becauseoftheimportanceofbeta
cell function for both the pathogenesis and the treatment of
T2D, the molecular pathways regulating insulin secretion are
of high interest.
Eny2 is a small (12kD), highly conserved nuclear protein
that is probably expressed ubiquitously. Its orthologs in yeast
and drosophila are termed Sus1 and E(y)2, respectively. Eny2
is a component of the SAGA/TFTC histone-acetyltransferase
complex that acts in transcriptional activation [5]. It is
also a part of the TREX-2/AMEX complex that mediates
mRNA export from the nucleus [6]. Additional functions
includeparticipationinmRNPformation[7]andthebarrier
activity of genomic insulators [8]. Eny2 is therefore thought
to be a coupling factor that integrates mRNA transcription,
processing, and nuclear export [9].
We identiﬁed Eny2 as a diﬀerentially expressed gene
in microarray expression proﬁles of pancreatic islets from
pregnant and control mice (A.L.; unpublished). Pregnancy
is associated with fundamental changes of beta cell mass
and function in the maternal rodent pancreas. We therefore
hypothesized that Eny2 could have regulatory roles in islet
endocrinecells.Inthepresentstudywetestedthishypothesis
in rat INS-1E insulinoma cells.2 Experimental Diabetes Research
2.MaterialsandMethods
2.1. Islet Isolation. To conﬁrm Eny2-expression in the islets
of Langerhans, islets from C57Bl/6 mice (Charles River
laboratories) were isolated by collagenase digestion of the
pancreas and selected by hand picking under a stereoscope
aspreviouslydescribed[10],followedbyRNAextractionand
rtPCR.
2.2. Cell Culture, Overexpression and Knockdown of Eny2.
INS-1E cells (passages 78–92) [11]w e r eag e n e r o u sg i f t
from Maechler and Wollheim (Geneva) and were cultured
at 37◦C and 5% CO2 in a humidiﬁed atmosphere in RPMI
1640 media (containing 11,1mmol/l glucose (PAA)) sup-
plemented with 5% heat-inactivated fetal calf serum (PAA),
100IU/mL penicillin (PAA),100μg/mL streptomycin (PAA),
10mMHEPES,1mMsodiumpyruvate(PAA),and50μMβ-
mercaptoethanol (Sigma-Aldrich). Cells were passaged every
5–7 days by trypsinization.
Transient overexpression of mouse Eny2 was done with
a pcDNA3 expression vector, which contained the mouse
Eny2-ORF under the control of a CMV-promotor. Roti
Fect Plus transfection reagent (Roth) was used following
the manufacturer’s protocol. In brief, INS-1 cells were
seeded in 24-well culture plates at a density of 1.5 × 105
cells/well and transfected within 1h after seeding with a
mixture of antibiotic-free culture media supplemented with
transfection reagent and either control-vector (pcDNA3) or
pcDNA3-Eny2/pcDNA3-Eny2-HA. The transfection media
was replaced with normal culture media after 24 hours.
To knock down endogenous Eny2 protein, transient
transfections with Eny2-speciﬁc siRNA (Silencer select;
Ambion) was performed using Lipofectamin RNAi MAX
(Invitrogen) following the manufacturer’s reverse transfec-
tion protocol. INS-1E cells were seeded in 24-well culture
plates at a density of 1.5 × 105 cell/well. The wells contained
complete culture media without antibiotics premixed with
control or Eny2-speciﬁc siRNA/Lipofectamin complexes
(100nM siRNA, 1,5μL Lipofectamin). Cells were then
cultured without any further media replacement until the
assays were done. 72–96 hours eﬀective mRNA suppression
was conﬁrmed by rtPCR. The siRNA sequences were as
follows: GCGAUUAACCAAAAGUUAA (Eny2-siRNA1),
AAAGGACUAGAACACGUUA(Eny2-siRNA3),AAUUGU-
UCGACUUUCUUGG (control).
2.3. RNA Isolation and Semiquantitative rtPCR. Total RNA
was isolated by RNeasy Mini Kit in combination with
DNA removal columns obtained from Qiagen. cDNA was
synthsized from total RNA with oligo(dT) primers and
the ImProm-II Reverse Transcription system (Promega).
Semiquantitative rtPCR was done with the Tag PCR Core
Kit (Qiagen) and GAPDH, cyclophilin, and beta actin for
normalization. Negative controls (-rt) were done for all
reactions and PCR products were sequenced to conﬁrm
their correct identity. The minimal necessary cycle number
was determined for each amplicon to achieve a reliable
semiquantitative ampliﬁcation. The primer sequences were
CTGTTGATGACTTGGTGGC and TTCAGCCACCAA-
GTCATCAA-3  forEny2(mouse),CTTAGGTGCCCGAGC-
TACTG and TTGCTAACCACCATCACCGC for Eny2 (rat),
AACTTTGGCATTGTGGAAGG and ACACATTGGGGG-
TAGGAACA for GAPDH (mouse), GGCATTGCTCTC-
AATGACA and TGTGAGGGAGATGCTCAGT for GAPDH
(rat), CACCTTTGTGGTCCTCACC and CCAGTTGGT-
AGAGGGAGCA for insulin 1 (rat), AATTTCATCATC-
GCCCTCTGandGTCTCTGATGACCCCAGGAAforGlut2
(rat), TCAGGACTTGCACTTTCACG and ACTCTCCTG-
GGGTCTGGTCT for glucokinase (rat), CCTGGAGGC-
CATTGTAGAAA and GGACATTGTTGCTGATGGTG for
phosphofructokinas (rat), GTGTGTGGTCTTTGGGAAGG
and TACAGGGTATTGCGAGCAGA for cyclophilin (rat),
AGCCATGTACGTAGCCATCC, and GCTGTGGTGGTG-
AAGCTGTA for β-actin (rat).
2.4. Measurement of Insulin Secretion and Insulin Content.
Following a transfection period (72h for overexpression
experiments;72–96hforsiRNA-mediatedknockdown)INS-
1E cells were washed twice in Krebs-Ringer-Bicarbonate-
Hepes buﬀer (KRBH; 135mM NaCl, 3.6mM KCl, 1.5mM
CaCl2,0 . 5 m MN a H 2PO4,0 . 5 m MM g C l 2,a n d5 m M
NaHCO3, 10mM HEPES) buﬀer containing 0.1% BSA and
were preincubated at 37◦C for 30min with the same buﬀer.
Subsequently, cells were incubated for another 30min in
0,5mL KRBH buﬀer supplemented with 0.1% BSA, diﬀerent
glucose concentrations, and other secretagogues, as indi-
cated in the ﬁgure legends (tolbutamide (Sigma); exendin-
4 (Byetta, Lilly); Forskolin (Sigma), 8-(4-chlorophenylthio)-
2 -O-methyladenosine-3 ,5 -cyclic monophosphate and N6-
benzyladenosine-3 ,5 -cyclic monophosphate (Biolog Life
Science), H-89 (Calbiochem)). Supernatants were collected
for measurements of secreted insulin. The attached cells
were extracted with lyses buﬀer (50mM HEPES, 0.1%
Triton X-100, 1mM DTT, 1x protease inhibitor cocktail
(Roche)) to determine the protein and insulin content.
Insulin was assayed by ELISA (Millipore; Linco) following
the manufacturer’s protocol.
2.5. Glucose-Dependent MTT-Assay. Glucose metabolism
was assessed by an MTT (C,N-diphenyl-N -4,5-dimethyl
thiazol 2 yl tetrazolium bromide) assay, which measures
cytoplasmaticreductionequivalentsresultingfromglycolysis
and mitochondrial oxidation [12].
INS-1E cells were reverse-transfected with either scram-
bled or targeting siRNA as described and seeded in 24-well
culture plates. 72–96h after transfection, cells were washed
and preincubated with glucose-free KRBH buﬀer at 37◦Cf o r
30min. Subsequently, cells were washed again and incubated
for another 30min period at 37◦C with 0,5mL KRBH
buﬀer supplemented with diﬀerent glucose concentrations
and MTT reagent (0.5mg/mL). For solubilization of the
produced formazan crystals, the KRBH buﬀer was replaced
by 1mL isopropanol/10%-DMSO solution. The absorbance
of the formazan was then measured with a photometer
(Eppendorf) at 550nm.Experimental Diabetes Research 3
2.6.AssessmentofCellularProliferation/Viability. Afteranin-
cubationtimeof72h,siRNAtransfectedINS-1Ecells,seeded
in 24-well cultures plates were incubated with MTT-reagent
(0,5mg/mL) without any further media replacement. After
an incubation period of 1,5h the media MTT solution was
replaced by isopropanol/10% DMSO and 5minutes later the
absorbance of produced formazan was measured at 550nm.
2.7. cAMP Assay. For measurement of cAMP formation,
INS-1E cells were treated with siRNA, seeded in 24-well
platesandculturedfor72–96h.Cellswerethenwashedtwice
with KRBH buﬀer, preincubated with the same buﬀer at
37◦C for 30min, washed once again followed by incubation
with 0.5mL KRBH buﬀer containing 16.7mM glucose with
orwithoutdiﬀerentconcentrationsofexendin-4and100μM
IBMX (3-isobutyl-1-methylxanthine (Sigma)). cAMP was
extracted after 5–15 minutes by adding 0.1mol/l HCl/0.5%
Triton X-100 to the cells. After a centrifugal step at 600g for
10min, the level of cAMP was measured in the supernatant
by using a competitive cAMP ELISA (Thermo Scientiﬁc).
2.8. Statistical Analysis. All results are expressed as mean
± standard deviation. The unpaired t-test was used for
comparisons of 2 experimental conditions. For 3 or more
conditions one-wayANOVAfollowed byposttests of selected
comparisons (Bonferroni method) was used.
3. Results
3.1. Eny2 mRNA Is Expressed in Mouse Pancreatic Islets
and Rat Insulinoma Cells: Suppression by siRNA. Our ex-
periments started from a microarray expression proﬁling
experiment that compared C57BL/6 islets from day 12.5
pregnant and control females (A.L.; unpublished). ENY2
was signiﬁcantly upregulated on day 12.5 when beta cell
proliferation is at its highest level during the adaptation of
the maternal pancreas to pregnancy.
We next conﬁrmed the expression of Eny2 mRNA in
islets from C57Bl/6 mice using rtPCR and also in rat INS-
1E insulinoma cells [11]( Figure 1(a)). INS-1E cells were
then used in functional studies. We ﬁrst tested several Eny2-
speciﬁc siRNAs for eﬃcient gene knockdown in this cell
line. Because no antibody towards mammalian Eny2 was
available, we examined Eny2 expression on the mRNA level.
siRNAs 1 and 3 suppressed Eny2 mRNA after 72–96 hours
(Figure 1(b)) and were used in further experiments.
3.2. Eny2 Knockdown Results in Increased Glucose-Stimulated
Insulin Secretion (GSIS) from Otherwise Poorly Functioning
INS-1E Cells. To test if Eny2 aﬀects the function of insulin-
producing cells we ﬁrst constructed an expression vector for
mouse Eny2. (The protein sequences of mouse and rat Eny2
are identical.) No change in glucose and exendin-4-induced
insulin secretion was observed after transient overexpression
of mouse Eny2 (Figure 2(a)). During the course of these
experiments we found however that the INS-1E cells in our
lab had developed a low-glucose responsiveness compared
to the original INS-1E line 1.7- versus 4.3-fold [11, Figure
Islets INS-1E
+ − + − rt
Eny2
GAPDH
(a)
Ctrl 1 3 siRNA
Eny2
GAPDH
(b)
Figure 1: RT-PCR detection of Eny2 mRNA expression in mouse
pancreatic islets and INS-1E insulinoma cells: knockdown by two
speciﬁc siRNAs. (a) The mRNA of Eny2 was detected in isolated
mouse pancreatic islets (left panel) and in INS-1E insulinoma cells
(right panel). (b) Eny2 mRNA is eﬃciently knocked down 72 hours
after transfection of INS-1E cells with 2 speciﬁc siRNAs (numbers 1
and 3) but not with a scrambled control siRNA.
2(a)]. We nevertheless also performed knockdowns of Eny2
in these cells using the two tested and eﬀective gene-speciﬁc
siRNAs. We compared glucose-stimulated insulin secretion
in the knockdown cells to that of cells treated with a scram-
bled control siRNA. Insulin secretion was augmented with
both Eny2-speciﬁc siRNAs in a glucose-dependent manner
(Figure 2(b)). Stimulation of insulin secretion from 2.8mM
to 16.7mM glucose was 1.9-fold for siRNA 1 (from 87 ±
26pg/μgp r o t e i n ∗30min to 162 ±34pg/μgp r o t e i n ∗30min;
P<0,05) and 2.7-fold for siRNA 3 (from 88 ± 24pg/μg
protein∗30min to 233 ± 65pg/μgp r o t e i n ∗30min; P<
0,05).
3.3. Insulin Content, Cellular Proliferation, and Key Compo-
nents of Glucose Sensing Are Unchanged after Eny2 Suppres-
sion. To examine the mechanism of increased GSIS after
Eny2 knockdown we ﬁrst measured cellular insulin content,
which was unchanged (Figure 3(a)). Cellular proliferation
was also not aﬀe c t e db yE n y 2s u p p r e s s i o n .7 2h o u r sa f t e r
seeding equal numbers of INS-1E cells per well and trans-
fection with either Eny2-speciﬁc siRNA or a control, cellular
viability was comparable (Figure 3(b)). Cellular protein
content was equally unchanged (data not shown). We next
examined the expression levels of insulin, the transcription
factor pdx1, and of several key components of glucose
sensing (Glut2, glucokinase, phosphofructokinase) using4 Experimental Diabetes Research
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Figure 2: GSIS by INS-1E cells after overexpression of Eny2 and siRNA-mediated Eny2 knockdown. (a) Mouse Eny2 was transiently
overexpressed in INS-1E cells by plasmid transfection. No change of glucose and exendin-4-induced insulin secretion was observed 72 hours
after transfection (n = 3). (b) Glucose-dependent insulin secretion was increased 72–96 hours after transfection with two diﬀerent Eny2-
speciﬁc siRNAs compared to a control siRNA (n = 5). ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001; the unpaired t-test was used for comparisons
between two experimental conditions, one-way ANOVA with posttests when 3 or more conditions were analyzed.
semiquantitative rtPCR. GAPDH, cyclophilin and beta-actin
were used as controls. No change in the expression levels of
any of the genes was observed (Figure 3(c)).
3.4. Eny2 Knockdown Results in a Higher Glucose-Dependent
MetabolicActivity. GSISfrompancreaticbetacellsiscoupled
to glucose metabolism [13]. Therefore we wanted to test
whether Eny2 knockdown aﬀected the cells’ metabolic
activity. Glycolysis results in pyruvate production, which
enters the mitochondria and is further metabolized in
the tricarboxylic acid (TCA) cycle. This results in the
production of the reducing equivalents NADH and FADH2
[13]. We used an MTT assay to measure glucose-dependent
production of reducing equivalents and thus to indirectly
quantify cellular glucose metabolism [12, 14]. We found
that reduction of MTT increased with increasing glucose
concentrations (2,8 to 16,7mmol/l) in both the control and
the Eny2-knockdown cell, but that the degree of increase
wassigniﬁcantlyhigherwithEny2suppression(Figure 3(d)).
Addition of exendin-4 to 16,7mmol/l glucose in both groups
did not signiﬁcantly alter MTT reduction. We also tested the
response to the sulfonylurea secretagogue tolbutamide. The
response to tolbutamide was minimal in control cells but
clearly present in cells with Eny2 suppression (Figure 3(e)).
Since tolbutamide-induced insulin secretion is not directly
dependent on glucose metabolism, this ﬁnding suggests
additional changes in Eny2 knockdown cells that contribute
to the increase in regulated insulin secretion.
3.5. Eny2 Suppression Enhances Incretin-Mediated Insulin
Secretion Downstream of cAMP. Incretin signaling via
glucagon-like peptide 1 (GLP-1) and gastric insulinotropic
peptide (GIP) is a central physiologic regulator of insulin
secretion in vivo [15]. We therefore tested whether suppres-
sion of Eny2 also aﬀects this pathway. Eny2 siRNA and con-
troltransfectedcellswerestimulatedwith50nmol/lexendin-
4 in addition to 16,7mmol/l glucose. In this experiment
suppression of Eny2 increased the exendin-4 induced aug-
mentationofinsulinsecretion,bothinabsolute(Figure 4(a))
and in relative terms (Figure 4(b)). A comparable eﬀect
was achieved with the adenylyl cyclase activator forskolin
(Figure 4(c)). To further evaluate the mechanisms by which
Eny2 aﬀects incretin signaling we measured cellular cAMP
levels after stimulation with exendin-4. The dose-response
curve 5 minutes after stimulation and the time course of
cAMP accumulation were not aﬀected by Eny2 knockdown
(Figures 4(d)–4(f)). This indicated that Eny2 suppression
acts downstream of cAMP.
3.6. Eny2 Knockdown Exerts Its Eﬀect on Incretin Signaling
Mainly via Modulation of PKA and to a Lesser Extent of
EPAC Signaling. The cAMP signal in beta cells is mainly
transmitted by two pathways, the protein kinase A (PKA)
and the EPAC pathway [16]. To investigate whether Eny2
suppression speciﬁcally aﬀects one of these two pathways we
ﬁrst compared insulin secretion after exendin-4 stimulation
with and without the PKA inhibitor H-89. H-89 reduced the
eﬀect of exendin-4 stimulation in Eny2 knockdown cells by
about 80% (Figure 5(a)). We also tested speciﬁc activators
of EPAC and PKA, 8-CPT-Me-cAMP, and N6-Bnz-cAMP
and compared those to forskolin (Figures 5(b) and 5(c)). In
this experiment the EPAC activator induced a small increase
of insulin release in Eny2 knockdown but not in control
cells. This eﬀect was not statistically signiﬁcant in terms of
absolute insulin values. However, when the relative increase
over 16,7mM glucose alone was analyzed, the eﬀect of theExperimental Diabetes Research 5
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Figure 3: Insulin content, cellular proliferation, gene expression, glucose metabolism, and response to tolbutamide after Eny2 knockdown.
(a) Cellular insulin content was measured 72 hours after transfection with control and Eny2-speciﬁc siRNA, respectively. Insulin content was
comparable after both treatments (n = 3). (b) INS-1E cells were seeded at low density and in equal numbers per well and were transfected
witheithercontrolorEny2-speciﬁcsiRNA.After3dayscellularviabilitywasquantiﬁedusingMTT.Nodiﬀerencebetweenthetwotreatments
wasobservedindicatingunchangedcellularproliferation(n = 3).(c)Theexpressionofseveralkeycomponentsofbetacellglucosesensingas
wellasofthetranscriptionfactorpdx1andinsulinitselfweremeasuredbysemiquantitativertPCR.GAPDH,cyclophilin,andbetaactinwere
used for normalization. No diﬀerence in the expression level of any of the genes was seen. (d) Glucose-dependent cellular metabolism was
e x a m i n e db ya nM T Ta s s a y( n = 3). The increase of metabolism with rising glucose concentrations was augmented after Eny2 knockdown.
(e) We also tested insulin secretion in response to the sulfonylurea secretagogue tolbutamide. Tolbutamide had a minimal eﬀect in control
cells but clearly augmented insulin secretion after Eny2 suppression. ∗P<0.05, ∗∗∗P<0.001 unpaired t-test.
EPAC activator was signiﬁcantly greater in cells after Eny2
suppression than in control cells (Figure 5(c)). Activation
of insulin secretion by the PKA activator N6-Bnz-cAMP
was signiﬁcantly enhanced in Eny2 knockdown compared to
control cells, both in absolute insulin values and relative to
16.7mM glucose alone (Figures 5(b) and 5(c)).
4. Discussion
In this study we show that the knockdown of the protein
Eny2 results in increased glucose and incretin-stimulated
insulin secretion from at baseline poorly responsive INS-1E
insulinoma cells. Eny2 is a multifunctional nuclear factor
that is involved in the initiation of gene transcription, mRNP
formation, and mRNA export from the nucleus [9]. It
participates in several diﬀerent nuclear protein complexes
[5–8] and has been described as a coupling factor that
helps connecting gene transcription and mRNA transport
[9]. It would seem logical that suppressing such a protein
disrupts cellular function; however, at least in transient
siRNA transfections over 72–96 hours and with no complete
suppression of the Eny2 mRNA, this was not the case6 Experimental Diabetes Research
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Figure 4: Insulin secretion in response to exendin-4 and forskolin after Eny2 knockdown: levels of cAMP. (a, b) INS-1E cells were stimulated
with 50nmol/l exendin-4 72 hours after transfection with either control or two diﬀerent Eny2-speciﬁc siRNAs. Insulin secretion in response
to exendin-4 was augmented by the two speciﬁc siRNAs, both in absolute (a) and relative terms (b) (n = 5). (c) Insulin secretion after
stimulationwith50nmol/lexendin-4and10μmol/lforskolin,whichledtocomparablesecretoryresponses.(d)INS-1Ecellswerestimulated
with diﬀerent concentrations of exendin-4 for 5 minutes. The concentration of cellular cAMP was measured by a competitive ELISA. (e, f)
Time course of cellular cAMP levels after stimulation with 50nmol/l exendin-4 in absence (e) and presence (f) of 100μmol/l IBMX. In both
setups the knockdown of Eny2 did not aﬀect cellular cAMP levels. ∗P<0,05, ∗∗P<0,01, ∗∗∗P<0,001; one way ANOVA with posttests
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Figure 5: Exendin-4 signaling downstream of cAMP, via PKA and EPAC. (a) Insulin secretion from INS-1E cells treated with 50nmol/l
exendin-4 with and without the PKA inhibitor H-89. Exendin-4 induced insulin secretion from Eny2-knockdown cells was reduced by 80%
with PKA inhibition. (b, c) Insulin secretion after stimulation with forskolin, the EPAC-speciﬁc activator 8-CPT-Me-cAMP, and the PKA-
speciﬁc activator N6-Bnz-cAMP; ((b) absolute values; (c) secreted insulin relative to 16.7mmol/l glucose alone). PKA-speciﬁc activation was
enhanced in Eny2 knockdown cells, both in absolute insulin values and relative to 16.7mM glucose alone. The EPAC activator 8-CPT-Me-
cAMP was active in cells after Eny2 suppression but not in control cells. This eﬀect was not statistically signiﬁcant with respect to absolute
insulin values but in relative terms (c). ∗P<0,05, ∗∗P<0,01, ∗∗∗P<0,001; one-way ANOVA with posttests and unpaired t-test.
in our study. Our results were obtained with two Eny2-
speciﬁc siRNAs with conﬁrmed activity and a scrambled
siRNA control was used in all experiments. We therefore
believe that oﬀ-target eﬀects can reasonably be excluded.
The best results were obtained with an siRNA with only
partial suppressive activity. This suggests that an ideal level
of Eny2 exists for eﬃcient regulated insulin secretion and
that poorly functional INS-1E cells possibly accumulated an
overabundance of the protein.
We show that Eny2 suppression leads to higher glucose-
dependent production of cellular reducing equivalents. This
can in part account for the observed increased GSIS
[13]. Our results with the glucose-independent secretagogue
tolbutamide however suggest additional cellular mecha-
nisms. With respect to incretin signaling our data indicate
that Eny2 suppression acts downstream of cAMP, mainly
via the PKA and to a smaller extent via the EPAC pathway.
However, we have not yet determined the exact molecular
m e c h a n i s mo ft h a te ﬀect.
The INS-1E cells in our lab turned out to be signiﬁcantly
less glucose responsive than the parental INS-1E line [11].
Subtle diﬀerences in culture conditions or the preferential8 Experimental Diabetes Research
growth of poorly glucose responsive INS-1E subclones are
probably responsible. Whether our results can be replicated
in fully functional INS-1E cells needs to be determined in
additional studies.
In several aspects our ﬁndings are similar to the results
of previous studies that compared subclones of Ins-1 cells
with diﬀerent responsiveness to glucose [17]. Pyruvate
cycling pathways were found to correlate with GSIS in the
diﬀerent clones [18]. These metabolic pathways result in the
accumulation of cytoplasmatic NADPH, which is in good
agreement with our measurements of reducing equivalents
in the MTT assay [12, 14]. In another report Yang et al. ﬁnd
that enhanced PKA signaling is linked to increased glucose
and forskolin-induced insulin secretion in the same Ins-1
sublines [19]. This is also the case after Eny2 knockdown in
our INS-1E cells.
Our study has three main limitations: ﬁrst of all we used
aninvitrosystemandaclonalcelllineandthereforecanonly
speculateon therelevanceof ourﬁndings in vivo. Second, no
antibody against mammalian Eny2 is currently available. We
therefore had to rely on mRNA measurements to quantify
Eny2 expression. Third, a gap of knowledge still remains
between the established nuclear functions of Eny2 and the
cellular phenotype we observed upon its suppression. Due
to the multiple roles of Eny2 this gap cannot be easily closed.
Transcriptomics,proteomics,orfunctionalscreeningwithan
siRNA library would be reasonable starting points.
5. Conclusions
Weidentiﬁedanunexpectedlinkbetweenthenuclearprotein
Eny2 and insulin secretion from a poorly glucose-responsive
INS-1E subline. Suppression of Eny2 results in increased
glucose and incretin-induced insulin release in these cells.
Whether these ﬁndings extend to other experimental con-
ditions or to in vivo physiology needs to be determined in
further studies.
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